1 Scientific blueprint for TB drug development, the Global Alliance for TB Drug Development fonim. [EB/OL]. hllp://WWW. thalliance.org
2 Andries K , Verhasselt P, Guilemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J]. Science, 2005,14,307(5707) :223-227
3 Igarashi M,Nakagawa N , Hatlori S et al. Capra/amycin A-F, novel anti-TB antibiotics from Streptomyces sp. (C) Abstr [M]. 42nd ICAAC, ASM .Washington, DC.2002:232
4 Stover CK, Warrener P, VanDevanter DR,et al. A small molecule nitroim-ida/opyran drug candidate for the treatment of tuberculosis [J].Nalure,2000,405(6789): 962-969
5 McCune RM,Tompsett K, McDermott. Fate of Mycobacterium tuberculosis in mouse tissues as delennined by the microbial enumeration technique[J]. J. Exp. Med, 1956,104 : 763-801
6 Cole ST. Comparative mycobacterial genomics us a tool for drug target and antigen discovery[J].Eur Respir J,2000,(S): 36,78-86
7 McKinney JD. In vivo Veritas: the search for TB drug targets goes live[J].Nature Medicine,2000,6(12) :1330-1333
8 Segal W,Bloch H. Biochemical differentiation of Mycobacterium tubercu-losis grown in vivo and in vitro[J]. J Bcteriol, 1956,72:132-141
9 Berthet FX. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene[J].Science, 1998,282:759 -762
10 Glickman MS,Cox JS, Jocob WR Jr. A novel mycolic acid cycloprapane synthetase is required for coding, persistence, and virulence of Mycobacterium tuberculosis[J]. Mol Cell ,2000,5 :717-727
11 The Times of India. Tuesday, September 07 , 2004. Indian scientists discover a new molecule against TB
|